BioInvent-Emerging best efficacy and safety profile in NHL-06/11/2026

Research evidence excerpt

BioInvent-Emerging best efficacy and safety profile in NHL-06/11/2026

BioInvent

NEWSFLASH | 11 JUN 2026

Emerging best efficacy and safety profile in NHL

BioInvent presented promising clinical updates for both programs at EHA 2026. For BI-1808 in advanced CTCL, topline

efficacy remains strong - 40% ORR as monotherapy and 50% with pembrolizumab. For BI-1206 in relapsed/refractory NHL,

the triplet combination delivered 11 CRs and 8 PRs, with all patients at least achieving stable disease - a 100% DCR. In the

follicular lymphoma (FL) subset, 81% ORR and 44% CR rate match the recently approved tafasitamab+R2, but with a much

cleaner safety profile. The company is hosting a KOL lunch at 11:45 CET today (link).

Dan Akschuti

+41 445 51 3823, da@paretosec.com

Chien-Hsun Lee

+41 445 51 3822, chien-hsun.lee@paretosec.com

For disclosures on relevant definitions, methods, risks, potential conflicts of interests etc. and disclaimers please see www.paretosec.com. Investment Recommendations should be reviewed in

conjunction with the information therein. When distributed in the US: This document is intended for institutional investors and is not subject to all of the independence and disclosure standards

applicable to equity/debt research reports prepared for retail investors. This material is considered by Pareto Securities to qualify as an acceptable minor non-monetary benefit according to Directive

2014/65/EU Article 24 (7)(8) and Commission Delegated Directive 2017/593.

Pareto Securities © 2026 1